PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

Background: Considering their mode of action, it is expected that the efficacy of thrombopoietin receptor‐agonists (TPO‐RAs), eltrombopag (ELT) and romiplostim, depends on their continuous administration. However, durable remissions after their discontinuation have been described in 10–30% of ITP patients (pts), suggesting a possible immunomodulatory activity. Aims: The aim of this prospective study is to explore the role of ELT given for a...